Arcus Biosciences' Promising Outlook with Casdatifan Development
- Citigroup analyst sets a price target of $46 for Arcus Biosciences (NYSE:RCUS), indicating a potential increase of approximately 35.86%.
- Casdatifan, a HIF-2a inhibitor, shows promising clinical data for treating metastatic kidney cancer, suggesting its potential as a best-in-class treatment.
- RCUS's current market capitalization stands at approximately $1.63 billion, with a trading volume of 1,945,156 shares, reflecting investor interest and stock liquidity.
Arcus Biosciences (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. Recently, Yigal Nochomovitz from Citigroup set a price target of $46 for RCUS, suggesting a potential price increase of approximately 35.86% from its current trading price of $17.42. This optimistic outlook is supported by promising clinical data for its HIF-2a inhibitor, casdatifan.
At the 2024 EORTC-NCI-AACR Symposium in Barcelona, Arcus presented data on casdatifan, highlighting its potential as a best-in-class treatment for metastatic kidney cancer. Dr. Toni K. Choueiri from the Dana-Farber Cancer Institute emphasized casdatifan's ability to rapidly control tumor growth, showing high response and disease control rates. This positions casdatifan as a promising future treatment option.
RCUS is currently priced at $17.83, reflecting a price change of $0.50, or an increase of approximately 2.89%. The stock has fluctuated between a low of $17.32 and a high of $18.98 during the day. Over the past year, RCUS has reached a high of $20.31 and a low of $12.95, indicating some volatility in its trading pattern.
The company's market capitalization is approximately $1.63 billion, with a trading volume of 1,945,156 shares. This market cap reflects the total value of the company's outstanding shares, providing insight into its size and investor interest. The trading volume indicates the level of activity and liquidity in the stock, which is crucial for investors considering buying or selling shares.
| Symbol | Price | %chg |
|---|---|---|
| 207940.KS | 1080000 | 5.74 |
| 068270.KS | 178600 | 1.4 |
| 196170.KQ | 449000 | 5.68 |
| 091990.KQ | 75900 | 0 |
Arcus Biosciences' Promising Outlook with Casdatifan Development
- Citigroup analyst sets a price target of $46 for Arcus Biosciences (NYSE:RCUS), indicating a potential increase of approximately 35.86%.
- Casdatifan, a HIF-2a inhibitor, shows promising clinical data for treating metastatic kidney cancer, suggesting its potential as a best-in-class treatment.
- RCUS's current market capitalization stands at approximately $1.63 billion, with a trading volume of 1,945,156 shares, reflecting investor interest and stock liquidity.
Arcus Biosciences (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. Recently, Yigal Nochomovitz from Citigroup set a price target of $46 for RCUS, suggesting a potential price increase of approximately 35.86% from its current trading price of $17.42. This optimistic outlook is supported by promising clinical data for its HIF-2a inhibitor, casdatifan.
At the 2024 EORTC-NCI-AACR Symposium in Barcelona, Arcus presented data on casdatifan, highlighting its potential as a best-in-class treatment for metastatic kidney cancer. Dr. Toni K. Choueiri from the Dana-Farber Cancer Institute emphasized casdatifan's ability to rapidly control tumor growth, showing high response and disease control rates. This positions casdatifan as a promising future treatment option.
RCUS is currently priced at $17.83, reflecting a price change of $0.50, or an increase of approximately 2.89%. The stock has fluctuated between a low of $17.32 and a high of $18.98 during the day. Over the past year, RCUS has reached a high of $20.31 and a low of $12.95, indicating some volatility in its trading pattern.
The company's market capitalization is approximately $1.63 billion, with a trading volume of 1,945,156 shares. This market cap reflects the total value of the company's outstanding shares, providing insight into its size and investor interest. The trading volume indicates the level of activity and liquidity in the stock, which is crucial for investors considering buying or selling shares.
